jRCT2080220997未知2 期
Phase 2 study of RK-023 patients with androgenetic alopecia (male pattern baldness) -A study for safety and preliminary estimation of hair re-growth in male subjects with androgenetic alopecia treated for 13 weeks with RK-023-
试验速览
- 阶段
- 2 期
- 入组人数
- 48
- 主要终点
- Number of cases with side-effects
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 干预模型
- Double-blind, randomised, placebo-controlled study
入排标准
- 年龄范围
- 20age old over 至 44age old under（—）
- 性别
- Male
入选标准
- •Men aged between 20 and 44 years with an androgenetic alopecia rated as Takashima modified classification of Norwood-Hamiltonstage, IIv, IIIv and IV
排除标准
- •Subjects with the complication that treatment is required
结局指标
主要结局
Number of cases with side-effects
Safety
Change for anagen hair ratio
Efficacy
Clinical valuation
Safety
Phototrichogram
Efficacy
次要结局
未报告次要终点
研究者
相似试验
未知
2 期
Phase 2 study of RK-023 patients with androgenetic alopecia (male pattern baldness) -A study for safety and preliminary estimation of hair re-growth in male subjects with androgenetic alopecia treated for 13 weeks with RK-023Androgenetic alopecia (male pattern baldness)JPRN-jRCT2080220997R-Tech Ueno, Ltd48
未知
1 期
A Phase 1 study of TAK-385 in Patients With Androgen Deprivation Treatment-Naive Prostate CancerjRCT2080222485TAKEDA PHARMACEUTICAL COMPANY LTD.43
进行中（未招募）
Unknown
Testing the addition of new treatments to standard treatment in prostate cancer that has spread to other areas of the bodyMetastatic hormone-sensitive prostate cancerCancerISRCTN66357938niversity College London4,914
终止
2 期
Phase II pre-operative study of Androgen Deprivation Therapy (Degarelix) and Erdafitinib in high-risk localized prostate cancer.Cancer - ProstateProstate CancerACTRN12618001061224Melbourne Health (The Royal Melbourne Hospital)9
进行中（未招募）
不适用
A prospective randomised phase III study of androgen deprivation therapy with or without local radiotherapy with or without abiraterone acetate and prednisone in patient with metastatic hormone-naïve prostate cancer. - GETUG-AFU 21EUCTR2012-000142-35-ITICANCER916